The study focuses on people with advanced Sarcoma, a rare cancer that begins in the body’s connective tissues. Two specific forms are included: Osteosarcoma, which starts in bone, and Soft tissue sarcoma, which begins in muscle, fat, or other soft tissues. The investigational medication being tested is Risvutatug Rezetecan (code name GSK5764227), which is given by an IV infusion, meaning it is delivered directly into a vein. The term “unresectable” means the tumor cannot be removed by surgery, “metastatic” means the cancer has spread to other parts of the body, and “relapsed/refractory” describes cancer that has returned or did not respond to earlier treatments.
The purpose of the study is to evaluate the efficacy and safety of the drug in participants whose disease has progressed after at least one prior line of systemic therapy. Participants will receive the medication in a series of treatment visits over several months, with regular check‑ups to see how the cancer is responding and to monitor any side effects. The study will continue until a predetermined follow‑up period is completed.
France 
